EuroPCR 2022 | The MITRA TUNE Registry

Left atrial enlargement with or without atrial fibrillation (AF), absence of valvular degeneration, and heart failure with preserved function have recently been identified as functional atrial mitral regurgitation (MR). This subtype of secondary MR currently appears to be underdiagnosed, and the need for treatment in the general population might be greater than predicted.

The MITRA TUNE Registry

The aim of this multicenter study was to analyze the 30-day and 2-year clinical and echocardiographic outcomes of patients who underwent transcatheter mitral valve repair.

Inclusion criteria were functional mitral insufficiency 3+/4+, LV diastolic diameter <55 without motility disorders; persistent, permanent, or paroxysmal AF, and normal valvular structure. 

Of the 1135 patients, 87 met the inclusion criteria. Mean patient age was 81 years old, and most subjects were female (61%). The Society of Thoracic Surgeons (STS) score was 4%. Technical success was 97%. The in-hospital death rate was 2%, the acute renal failure rate was 8%, and the major bleeding rate was 4.5%. At 30 days, the total mortality rate was 5% and the rate for cardiovascular death was 4%.

Mild or moderate MR was present in 98% of patients, and symptomatic improvement was observed in 79% of patients with functional class I/II within the first year of follow-up.

Echocardiographic analysis of the left atrium showed significant positive remodeling compared with baseline values and control outcomes within the first year. 

Read also: DISCO RADIAL: Conventional or Distal Transradial Access?

The rate for cardiovascular survival and hospitalization for heart failure in these patients was 55% at 2 years. A multivariate analysis showed that postprocedural MI ≥2+ and intercommissural annular diameter ≥35 mm were independent negative predictors.

Conclusion

In patients with functional atrial MR, transcatheter edge-to-edge repair of the mitral valve was shown to be safe and effective, inducing positive reverse remodeling of the left atrium and mitral annulus, improving symptoms.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org.

Original Title: MItraClip in Atrial Functional mitral regurgitation: a multi-center experience. The MITRA TUNE Registry. 

Reference: Antonio Popolo Rubbio, et al. EUROPCR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...